Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) Eligible patients were randomly ...
April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...
Please provide your email address to receive an email when new articles are posted on . Significantly more patients who received luspatercept vs. epoetin alfa achieved the study’s primary endpoint of ...
Dec. 9, 2004 -- The U.S. Food and Drug Administration (FDA) and Ortho Biotech Products warned healthcare professionals via letter of important information regarding the safe dosing of epoetin alfa ...
CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the ...
The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California. Updated results from the primary analysis of the phase ...
Pegmolesatide appears as effective as epoetin alfa and can be administered at longer intervals. Monthly subcutaneous pegmolesatide maintains hemoglobin as effectively as conventional epoetin alfa in ...
Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients ...
In people with myelodysplastic neoplasms (MDS), a usually benign form of chronic lymphocytic leukemia, the body produces too few functional blood cells. Affected individuals suffer from anemia—a lack ...
Patients with myelodysplastic syndromes tended to have longer periods of time without needing a red blood cell transfusion when treated with Reblozyl. Patients with myelodysplastic syndrome (MDS) ...
SAN FRANCISCO (MarketWatch) -- Amgen Inc. said late Thursday a Phase III study has demonstrated that Aranesp dosed every two weeks resulted in similar clinical efficacy as Epoetin alfa dosed once a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results